Zanolife confirms its clients not impacted following Government of Hong Kong SAR Announcement regarding a potentially affected batch of flu vaccine in Hong Kong.

28 November, 2018

Zanolife confirms its clients not impacted following Government of Hong Kong SAR Announcement regarding a potentially affected batch of flu vaccine in Hong Kong.

By Zanolife
Zanolife would like to reassure its clients that they have not been impacted following the announcement yesterday made by health authorities with regards to the import and use of a potentially affected batch of flu vaccines in Hong Kong.
The brand of quadrivalent influenza vaccines currently supplied by Zanolife’s flu vaccine partner are manufactured by GlaxoSmithKline (GSK), not by the impacted company Sanofi.
According to a Government of Hong Kong press release yesterday (27 November 2018), authorities announced that the Department of Health had been informed by a licensed drug wholesaler, Sanofi-Aventis Hong Kong Limited (Sanofi), that it has decided to take a precautionary measure to suspend the market supply of a batch of quadrivalent seasonal influenza vaccines (SIVs) (box label: R3J721V; syringe label: R3J72) and arrange to dispatch a new batch of quadrivalent SIVs to local private healthcare facilities as soon as possible.